Positive: HUTCHMED announces positive results from Phase III study with savolitinib and osimertinib.

From GlobeNewswire: 2025-06-01 20:00:00

HUTCHMED announced positive results from the SACHI Phase III study, showing a significant PFS benefit with a favorable safety profile for the combination of savolitinib plus osimertinib in treating EGFR mutation-positive NSCLC with MET amplification. A webcast will be held to discuss the data on June 3, 2025. The combination demonstrated promising efficacy, with a median PFS of 8.2 months compared to 4.5 months with chemotherapy. The ORR was 58% in the treatment group. The safety profile was tolerable, with no new safety signals observed. Enrollment in the study has concluded, and a New Drug Application has been accepted for priority review. HUTCHMED focuses on developing drug candidates from in-house discovery to global patients. The company’s first three medicines are marketed in China, with one approved worldwide, including in the US, Europe, and Japan. For more information, visit www.hutch-med.com or follow on LinkedIn. The press release contains forward-looking statements regarding the therapeutic potential of savolitinib and its clinical development. Risks include enrollment rates, unexpected adverse events, and regulatory approval. Investors are advised to review risks in HUTCHMED’s filings. The press release also provides medical information about products that may vary by country. For investor and media inquiries, contact the provided numbers and emails.



Read more at GlobeNewswire: HUTCHMED Highlights SACHI Phase III Study Data Presented at